Skip to main content
. 2022 Oct 31;14(11):2416. doi: 10.3390/v14112416

Figure 2.

Figure 2

SARS-CoV-2 anti-IgG pre- and post-vaccination. Antibody signals in k = 21 paired participants, who re-ceived a COVID-19 vaccine during the study, at baseline and 14 to 56 days post-vaccination, presented by individ-ual SARS-CoV-2 antigen (k = 21): (A) anti-S, (B) anti-RBD, (C) anti-N. Differences in antibody signals were examined with a paired Wilcoxon signed rank test.